Knowledge, practice and acceptability of HPV vaccine by mothers of adolescent girls in Ilorin, Nigeria

Kikelomo  T. Adesina; Aishat  Saka; Salamat  A. Isiaka-Lawal; Omotayo  O. Adesiyun4; Grace  G. Ezeoke1

doi:10.52981/sjms.v13i1.1060

Kikelomo T. Adesina University of Ilorin
Aishat Saka University of Ilorin Teaching Hospital
Salamat A. Isiaka-Lawal Sobi Specialist Hospital,
Omotayo O. Adesiyun4 University of IlorinTeaching Hospital
Grace G. Ezeoke1 University of IlorinTeaching Hospital

DOI: https://doi.org/10.52981/sjms.v13i1.1060

Keywords: Human Papilloma Virus, HPV vaccine, prepubertal HPV vaccination, Adolescent girls’ vaccine, Ilorin

Abstract

Background: Human Papilloma Virus (HPV) is a sexually transmitted cause of carcinoma of the cervix. An important determinant of the success of a primary preventive strategy like HPV vaccination is the knowledge and willingness of parents to vaccinate adolescents before sexual debut.

Materials and methods of study: A cross sectional descriptive survey of mothers of girls in 8 secondary schools in Ilorin was carried out from February to April 2015. Schools were selected using multi staged sampling. Descriptive and inferential statistics were performed with Chi Square and ANOVA.

Results: There were 470 questionnaires returned for analysis out of 600, giving a response rate of 78.3%. One hundred and sixty-one (34.3%) knew HPV to be sexually transmitted infection and 40.4% knew it was the cause of cervical cancer. While 35.1% were aware of HPV vaccine, only 1.9% had ever vaccinated their children. Less than half (44.9%) were willing to vaccinate their children. Women with good knowledge of HPV and cervical cancer were more willing to vaccinate their children than women with poor knowledge (P <0.001).

Conclusion: There is poor knowledge of HPV and practice of vaccination among mothers in llorin. Willingness of mothers to vaccinate their daughters is suboptimal. Mother’s knowledge is an important determinant of HPV vaccination of adolescents

References

[1] Parkin DM, Bray F. The burden of HPV- related cancers. Vaccine 2006;24:11-25.
[2] WHO/ICO. Information on HPV and Cervical Cancer (HPV Information Centre).
Summary report on HPV and Cervical Cancer statistics in Nigeria. 2007 [cited 2013Feb 12]. Available from:www.who.int/hpvcentre.
[3] Kolawole AO. Cervical Cancer Prevention in Nigeria: Issues Arising. InternetJournal of Gynecology and Obstetrics. 2012 Jan[cited Feb 11];16(1). DOI:10.5580/2b20.Available from at: http://www.ispub.com/journal/the-internetjournal-of-genomics-and-proteomics.
[4] Adesina K, Saidu R, Aboyeji A, Fawole A, Olarinoye A, Ibrahim K. Factors contributingto low cervical cancer screening in a population at risk. Nig J Health Sci.2010;10:21-25.
[5] Ault KA. Effect of prophylactic human papillomavirus L1 virus-like particle vaccineon risk of cervical intraepithelial neoplasia grade 2,grade 3, and adenocarcinoma insitu: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–1868.
[6] Nnodu O, Erinosho L, Jamda M, Olaniyi O, Adelaiye R,Lawson L et al. Knowledgeand Attitudes towards Cervical Cancer and Human Papillomavirus: A Nigerian PilotStudy. African Journal of Reproductive Health 2010; 14:95-108.
[7] Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Xavier Bosch F ,Franco E .Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18vaccine. J Natl Cancer Inst 2004;96:604–15.
[8] Moraros J , Bird Y, Barney D.D ,King S.C ,Banegas M, Suarez-Toriello E. A Pilot Study:HPV Infection Knowledge & HPV Vaccine Acceptance among Women Residing inCiudad Juárez, México. Californian Journal of Health Promotion 2006; 4:177-186.
[9] Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.N Engl J Med 2007;356:1928–1943.
[10] D. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacyof a prophylactic adjuvanted bivalent L1virus-like-particle vaccine against infectionwith human papillomavirus types 16 and 18 in young women: an interim analysisof a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161–2170.
[11] Thomas JO, Hererro R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A et al.Prevalence of Human Papilloma Virus Infection in women in Ibadan,Nigeria: apopulation-based study. Br J Cancer 2004;90:638-645.
[12] Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation betweenhuman papillomavirus and cervical cancer. J Clin Pathol. 2002;55: 244-265.
[13] Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS.HPV vaccine acceptabilityamong Kenyan women. Vaccine2010;28: 4864–4867.
[14] Liu FW, Vwalika B, Hacker MR, Allen S, Awtrey CS. Cervical Cancer and HPVVaccination: Knowledge and Attitudes of Adult Women in Lusaka, Zambia. Journalof Vaccines & Vaccination 2012 doi: 10.4172/2157-7560.1000138
[15] Francis SA, Nelson J, Liverpool J, Soogun S, Mofammere N, Thorpe RJ. Examiningattitudes and knowledge about HPV and cervical cancer risk among female clinicattendees in Johannesburg, South Africa. Vaccine 2010;28: 8026–803
[16] Coleman MA, Levison J, Sangi-Haghpeykar H . HPV vaccine acceptability in Ghana,West Africa. Vaccine.2011; 29: 3945–3950.
[17] Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Manga S et al. Assessing theeffectiveness of a community-based sensitization strategy in creating awarenessabout HPV, cervical cancer and HPV vaccine among parents in North WestCameroon. Journal of community health.2012; 37: 917–926.
[18] Ayissi CA, Wamai RG, Oduwo GO, Perlman S, Welty E, Welty T et al. Awareness,Acceptability and Uptake of Human Papilloma Virus Vaccine among CameroonianSchool-Attending Female Adolescents. Journal of community health2012; 37: 1127–1135. doi: 10.1007/s10900-012-9554-z
[19] Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and of HPVvaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review.PLoS ONE2014; 9: e90912. doi:10.1371/journal.pone.0090912.
[20] Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centersfor Disease Control and Prevention (CDC); Advisory Committee on munizationPractices (ACIP) Quadrivalent Human Papillomavirus Vaccine: Recommendationsof the Advisory Committee on Immunization Practices (ACIP) MMWR RecommRep.2007;56(RR-2):1–24.
[21] Fisher WA, Laniado H, Shoval H, Hakim M, Bornstein J. Barriers to humanpapillomavirus vaccine acceptability in Israel. Vaccine 2013; 31: 153-157.